Related Experiment Video
Updated: Aug 10, 2026

Fractionation for Resolution of Soluble and Insoluble Huntingtin Species
Published on: February 27, 2018
Antisense downregulation of mutant huntingtin in a cell model
Lis Hasholt1, Kathrine Abell, Anne Nørremølle
1Section of Neurogenetics, Institute of Medical Biochemistry and Genetics, University of Copenhagen, Denmark. hasholt@imbg.ku.dk
Insights
Antisense oligonucleotides effectively reduce mutant huntingtin expression and aggregate formation in cellular models of Huntington's disease (HD). This suggests a potential therapeutic strategy for HD by downregulating the disease-causing protein.
Area of Science:
- Neuroscience
- Genetics
- Molecular Biology
Background:
- Huntington's disease (HD) is an inherited neurodegenerative disorder.
- Caused by CAG repeat expansion in the huntingtin (HD) gene, leading to mutant huntingtin protein.
- Pathological mechanisms involve mutant huntingtin expression and neuronal death.
Purpose of the Study:
- Investigate the potential of antisense technique to downregulate mutant huntingtin expression.
- Assess the effect of antisense oligonucleotides on huntingtin aggregation.
Main Methods:
- Transfection of NT2 cells and neurons with HD gene constructs.
- Treatment with phosphorothioated antisense oligonucleotides (PS-ASHD/20+) or control oligonucleotides.
- Monitoring of fusion protein expression and aggregate formation.
Main Results:
- Antisense oligonucleotides specifically inhibited fusion protein expression and aggregate formation.
- Effectiveness observed in both NT2 precursor cells and differentiated neurons.
- Antisense effect in NT2 cells was administration-dependent.
Conclusions:
- Phosphorothioated antisense oligonucleotides are effective in downregulating mutant huntingtin.
- Reduced aggregate formation serves as a sensitive biological marker for HD.
- Antisense huntingtin knockdown is a promising therapeutic strategy for HD and useful for cellular model studies.
Background:
Huntington's disease (HD) is an inherited neurodegenerative disorder which is caused by an expansion of a CAG repeat sequence in the HD gene. The repeat encodes an expanded polyglutamine tract in the protein huntingtin. The still unknown pathological mechanisms leading to death of specific neurons in the brains of HD patients correlate with the expression of mutant huntingtin. Therefore, we have studied whether mutant huntingtin expression can be downregulated by antisense technique.
Methods:
NT2 precursor cells and differentiated postmitotic NT2-N neurons, respectively, were transfected with plasmid constructs containing exon 1 of the HD gene with expanded CAG repeats in frame with the reporter protein EGFP. The transfected cell cultures were treated with a phosphorothioated antisense oligonucleotide (PS-ASHD/20+) or a control oligonucleotide either by cotransfection or by addition to the culture medium.
Results:
Expression of the fusion protein containing the mutant huntingtin fragment resulted in diffuse green fluorescence in the cytoplasm and formation of aggregates in some of the NT2 cells and NT2-N neurons. We obtained antisense sequence-specific inhibition of expression of the fusion protein and/or suppression of the aggregate formation in both cell types. In the NT2 cells the antisense effect was dependent on the way of administration of the oligo.
Conclusions:
The PS-antisense oligo is effective in downregulation of mutant huntingtin, and the reduction of aggregate formation is a sensitive biological marker. The findings suggest that antisense knockdown of huntingtin could be a useful strategy for treatment of HD, and could also be suitable for studies of the normal and pathological function of huntingtin in different cellular model systems.
More Related Videos
Related Concept Videos
Experimental RNAi
Huntington Disease l: Introduction

